Supercharging BRD4 with NUT in carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Genomics

Background:

• NUT carcinoma (NC) is an aggressive cancer lacking effective therapies, often driven by the BRD4-NUT fusion oncoprotein.
• BRD4-NUT recruits the histone acetyltransferase p300, leading to hyperacetylated nuclear foci called megadomains (MDs).
• MDs are massive chromatin regions co-enriched with BRD4-NUT, p300, and acetylated histones, potentially acting as super-enhancers.

Purpose of the Study:

• To investigate the function of BRD4-NUT-driven megadomains (MDs) in NUT carcinoma.
• To explore the potential of MDs as super-enhancers and their role in regulating key cancer-related transcription factors.
• To examine the novel nuclear sub-compartment, subcompartment M (subM), formed by MD interactions and its implications for genome organization and cell identity.

Main Methods:

• Proteomics to define the BRD4-NUT chromatin complex.
• Immunofluorescence to visualize nuclear foci and megadomains.
• Analysis of gene targets within megadomains, including MYC, SOX2, and TP63.

Main Results:

• BRD4-NUT forms megadomains (MDs) that span up to 2 megabases.
• MDs are enriched with BRD4-NUT, p300, and acetylated histones, suggesting super-enhancer activity.
• MDs regulate key stem cell transcription factors (MYC, SOX2, TP63) and form a novel nuclear sub-compartment (subM).

Conclusions:

• MDs represent a novel mechanism of oncogene-driven transcriptional dysregulation in NUT carcinoma.
• The formation of subM by MDs has broad implications for understanding 3D genome organization and cell identity.
• Understanding BRD4-NUT function provides a basis for developing targeted therapies, including BET inhibitors.